Knockdown of KIF20A enhanced the sensitivity of colorectal cancer cells to oxaliplatin and inhibited the activation of NUAK1, a kinase related to malignant progression and poor prognosis of CRC [84]. The gene discussed is NUAK1; the disease is colorectal carcinoma.